The key finding
A 2025 review published in NPJ Biofilms and Microbiomes examines how European regulators are adapting their frameworks to accommodate the rapidly growing field of microbiome-based therapies. The authors detail how the new Regulation on Substances of Human Origin (SoHO) introduces specific provisions for therapies that use bacteria, viruses, and other microorganisms from human donors to treat disease. These regulatory changes reflect the shift from viewing microbiome treatments as simple probiotics to recognizing them as complex biological interventions requiring specialized oversight—a transformation driven by the emergence of therapies like fecal microbiota transplantation and engineered bacterial consortia.
What the study looked like
This paper is a regulatory review rather than an experimental study. The authors, writing from European regulatory and scientific institutions, analyzed the evolving legal and scientific frameworks governing microbiome therapies in the European Union. They examined two main areas: first, they catalogued the spectrum of microbiome-based interventions currently in development, ranging from live bacterial products to metabolites derived from gut microbes. Second, they conducted a detailed analysis of the new SoHO regulation and compared it to previous regulatory approaches. The review focused on identifying gaps where current rules may not adequately address the unique characteristics of microbiome products—such as their complexity (containing hundreds of bacterial species), their variability between donors, and the difficulty of standardizing living biological materials.
Why researchers think this happened
The authors argue that traditional regulatory categories were designed for conventional drugs and couldn’t adequately accommodate microbiome therapies. A single-molecule drug can be characterized completely, but a fecal microbiota transplant contains thousands of bacterial strains, metabolites, and even bacteriophages—each batch potentially different. The SoHO regulation emerged because existing frameworks for either pharmaceuticals or human tissues didn’t fit: microbiome products aren’t simple chemicals, yet they’re more complex than organ transplants. The review emphasizes that regulators recognized the need for what the authors call “microbiome regulatory science”—new testing methods, quality standards, and safety assessments tailored to these living therapies. This regulatory evolution mirrors scientific understanding: researchers now view the microbiome not as a passive bystander but as an active therapeutic target, necessitating rules that can ensure safety while not stifling innovation in this emerging field.
How to read this carefully
This review describes regulatory frameworks rather than clinical evidence, so readers should understand it’s about the rules for testing microbiome therapies, not proof that such therapies work for specific conditions. The authors work within regulatory bodies and academic institutions, which provides expertise but may also reflect an institutional perspective favoring standardized pathways. The paper doesn’t provide data on how many microbiome therapies have succeeded or failed under different regulatory systems, nor does it compare European approaches to those in other regions like the United States or Asia. The call for “microbiome regulatory science” is aspirational—the specific methods and standards needed don’t all exist yet. Readers should recognize that stricter regulation can improve safety but may also slow the path from laboratory discovery to patient access.
What this means for everyday life
For anyone following health news about probiotics, gut health, or personalized medicine, this regulatory shift signals that microbiome therapies are moving from fringe treatments to mainstream medicine—but with appropriate guardrails. If you’ve wondered whether the probiotic supplements lining pharmacy shelves are truly effective, these new regulations distinguish between commercial probiotics (loosely regulated as foods or supplements) and prescription microbiome therapies that will require clinical trials and safety monitoring. The development suggests that within the next decade, doctors may prescribe specific bacterial mixtures for conditions ranging from inflammatory bowel disease to metabolic disorders, much as they now prescribe targeted cancer therapies. Given these changes, it might be worth distinguishing between unregulated wellness products and therapies that will eventually undergo rigorous testing under frameworks like SoHO—a difference that could matter significantly for both safety and effectiveness.